Skip to main content
TipRanks
Go Ultimate75% OFF

Eastwood Bio-Medical Canada (EBM) AI Stock Analysis

5 Followers
TSE:EBM

Eastwood Bio-Medical Canada

(TSXV:EBM)

Select Model
Rating:51Neutral
Price Target:CAD 1.50▼(-8.54% Downside)
Action:reiterated
Date:10/01/26

Severely strained balance sheet and unreliable cash flows are the dominant factors capping the score, despite supportive technical momentum and modest income statement progress; poor valuation from deep losses adds further pressure.

Positive Factors
Revenue reboundThe sharp TTM revenue rebound indicates that demand for the company’s products or services has recovered materially after earlier volatility. If sustained, stronger sales can improve operating leverage, support broader customer reach, and provide a larger base from which the business can pursue profitability.
Negative Factors
Deeply negative equityDeeply negative and worsening equity reflects accumulated losses and a weak capital base. It reduces financial flexibility, raises solvency and refinancing concerns, and can make it harder to fund growth or absorb operational setbacks without additional external capital.

Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)

-50%0%50%100%150%200%TSE:EBM+112.99%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 112.97M
Dividend Yield
―
Average Volume (3M)
7,194
Price to Earnings (P/E)
-529.0
Beta (1Y)
0.54
Revenue Growth
36.59%
EPS Growth
43.33%
Country
Canada
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Eastwood Bio-Medical Canada Business Overview & Revenue Model

Company Description

Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, t...

Eastwood Bio-Medical Canada Financial Statement Overview

Summary

Income statement shows modest revenue stabilization and narrowing losses, but this is outweighed by a severely negative equity balance sheet and weak operating cash flows, pointing to significant financial instability.

Income Statement

47Neutral

Balance Sheet

11Very Negative

Cash Flow

23Negative
Financial statement breakdown
BreakdownTTMJan 2026Jan 2025Oct 2023Oct 2022Jan 2022
Income Statement
Total Revenue812.12K782.08K702.08K867.94K1.30M981.05K
Gross Profit538.18K506.03K454.39K440.51K902.74K458.37K
EBITDA-238.60K-309.73K-342.05K-410.58K-32.33K-495.50K
Net Income-231.56K-332.77K-455.87K-546.60K-160.58K-611.34K
Balance Sheet
Total Assets256.96K218.77K274.29K489.14K584.53K691.12K
Cash, Cash Equivalents and Short-Term Investments3,52817.70K018.45K39.84K20.87K
Total Debt63.65K78.01K79.61K23.08K62.25K31.35K
Total Liabilities2.04M1.85M1.57M1.33M878.73K835.44K
Stockholders Equity-1.78M-1.63M-1.30M-840.80K-294.20K-144.32K
Cash Flow
Free Cash Flow-9,42019.30K-15.22K-16.89K-7,299-121.79K
Operating Cash Flow-9,42819.30K-15.22K-16.89K-4,294-116.21K
Investing Cash Flow0000-3,005-5,574
Financing Cash Flow-7,688-211-4,619-4,50326.27K20.00K

Eastwood Bio-Medical Canada Technical Analysis

Technical Analysis SentimentNegative
Last Price1.64

Price Trends

50DMA1.84Negative
100DMA1.58Positive
200DMA1.17Positive

Market Momentum

MACD-0.05Positive
RSI39.14Neutral
STOCH44.19Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 1.84, and above the 200-day MA of 1.17, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.14 is Neutral, neither overbought nor oversold. The STOCH value of 44.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EBM.

Eastwood Bio-Medical Canada Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:EBM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:EBMTSE:EBM51NeutralCAD 112.97M-529.0313.66%―36.59%43.33%
TSE:ARCHTSE:ARCH43NeutralCAD 63.86M-22.1274.79%――-15.53%
TSE:ATLETSE:ATLE42NeutralCAD 39.63M-0.76-2099.75%―-96.13%88.13%
TSE:SONATSE:SONA40UnderperformCAD 31.31M-11.91448.05%――24.65%
TSE:ADKTSE:ADK38UnderperformCAD 35.52M-6.669999.00%―-36.92%13.03%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%TSE:EBMTSE:ARCHTSE:ADKTSE:ATLETSE:ZYUSTSE:SONADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:EBM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:EBMEastwood Bio-Medical Canada1.640.88115.79%
TSE:ARCHArch Biopartners0.94-0.10-9.62%
TSE:ADKDiagnos Inc0.28-0.02-8.33%
TSE:ATLEWillow Biosciences0.09-0.06-39.29%
TSE:ZYUSZyus Life Sciences Corporation0.39-0.30-44.20%
TSE:SONASona Nanotech, Inc0.26-0.29-52.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026